April 2, on the first day of the collective stand of the St. Petersburg cluster, turned out to be quite eventful and interesting. The program of activities at the cluster stand covered the most pressing topics aimed at the development of innovations in the pharmaceutical industry.
At 12.00. As part of the Collective Stand of the St. Petersburg Cluster, the grand opening of the International Forum in the field of Pharmaceuticals and Biotechnology and the exhibition of pharmaceutical ingredients, production and distribution of medicines “IPhEBRussia 2019” took place. Dmitry Chagin , Chairman of the Board of the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union, at the opening noted the importance of the constant movement and development of the pharmaceutical industry, breakthrough technologies and spoke about the idea of organizing the I All-Russian Pharmaceutical Run, which aims to unite and create the necessary potential for domestic cooperation. Yuri Kalabin, Chairman of the Committee for Industrial Policy and Innovation of St. Petersburg, emphasized the importance of developing new technologies for both the city and the industry. It is important that there is a reliable partnership with Technopark of St. Petersburg, which supports the St. Petersburg cluster in all endeavors, acting as a powerful channel for promoting breakthrough industry technologies.
After the grand opening, the work program of the Collective Stand was launched. So, from 12.30. until 2 p.m. a lecture “New strategies for the treatment of orphan diseases” was held, in which the main emphasis was placed on analysis and forecasts of the development of the market for medicines for the treatment of rare diseases in the Russian and world context.
Following the lecture, at 14.00. A banking product for the pharmaceutical industry was presented on the basis of project financing of Sberbank of Russia PJSC. “I put this idea on Life Science Invest last year. Surprisingly, experts were able to quickly penetrate the specifics of our industry and create a product that not only gathered solutions to the problems voiced at the forum, but also took into account the depth and subtleties of the pharmaceutical industry processes. It is especially important that after obtaining approval from a credit institution, the decision is sent to the executive authorities of the federal subject, where these projects will be implemented. Thus, investment projects will be developed within a clear and transparent structure with the necessary support and interaction. This is a rare project that can optimize the activities of each involved party and help develop the industry’s potential, ”commented Dmitry Chagin .
After the presentation of the banking product, the presentation of the First All-Russian Pharmaceutical Run took place, within which Dmitry Chagin , Chairman of the Board of the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union Alexey Martynov , & nbsp; President of the BMKP Association (Association of Manufacturers of Biomedical Cellular Products), member of the ASI Expert Council (Agency for Strategic Initiatives), member of the Russian Union of Industrialists and Entrepreneurs (Russian Union of Industrialists and Entrepreneurs), CEO X-Biosell & nbsp; and Victoria Presnyakova , Executive Director of SRO “ASNA” spoke about the main agenda of the project and the stated problems: “National goals in the field of health. Priority Development Issues. ”
“Today we observe a high need for the pharmaceutical industry, the medical and patient communities in uniting and internal cooperation on the most urgent challenges and tasks of the entire healthcare system. In each city of the rally, thematic events and round tables will be organized on the issues of drug provision, national security, breakthrough technologies, and pricing in both the industrial and pharmacy segments. In addition, it is very pleasing that, in addition to the business program, Farmrobeg will include a charity line for the foundation of Ivan Demyan, the leader of the 7B rock group, “Time is Kinder”, said Anna Plesovskikh , representative of the technical operator, General Director interdisciplinary association “Farmrobeg”.
The most active and anticipated event within the framework of the Collective Stand was a round table: “Prospects for breakthrough technologies for the microreactor synthesis of pharmaceutical substances”.
“The creation of an innovative and scientific infrastructure in the field of critical technologies is the first step in city policy to ensure the possibility of pharmaceutical manufacturers localized in the territory of St. Petersburg to target export markets. This is the main and significant contribution of the city to the overall development of the pharmaceutical industry in Russia. Such infrastructure projects can increase efficiency and productivity, which is a direct solution to the tasks of the authorities. Already, the first results of research cooperation allow our companies to implement complex cross-border projects, which of course is a huge incentive for pharmaceutical companies to be based in St. Petersburg and achieve the targets set by the May decrees of the President, and national projects in the field of healthcare, demography and exports, ”said Dmitry Chagin .
Intensive microreactor synthesis of pharmaceutical substances and key intermediates is included in the list of breakthrough technologies in the pharmaceutical field, combining the high efficiency of synthesis methods with energy efficiency, environmental safety and low operating costs.
The development and use of microreactors is directly related to the development of technology for continuous flow reactions. This is a new direction in the technology of chemical and biological synthesis. Already, microreactor technologies can safely be called “future technologies.” Drawing parallels with computer technology, we can safely predict that in the very near future the picture in laboratories – both chemical and pharmaceutical, and biological – will change radically in the direction of a significant improvement in the productivity and efficiency of synthesis processes with significant miniaturization of devices and apparatuses.
RIC AFS is the only center in Russia for the development and implementation of technologies for the microreactor synthesis of AFS and organic substances. The concept of the RIC AFS provides a logical production chain for the development of flow microreactor synthesis technology from laboratory to semi-industrial / industrial scale.
“Based on the results of the & nbsp; 2017-2018. technological work of microreactor synthesis on a laboratory scale requires a mandatory stage – a pilot, i.e. development of stages of microreactor synthesis in regimes as close as possible to production. This ensures the scaling and implementation of technologies at the production sites of the RIC AFS Customers, ”said Elena Petrova , director of the Regional Engineering Center for the microreactor synthesis of active pharmaceutical substances of Technopark St. Petersburg JSC.
Due to the growth of the pharmaceutical market, as well as the emergence of cross-functional and promising tasks of professional activity, the pharmaceutical industry has developed a need for a new type of personnel capable of solving non-trivial tasks, such as mastering critical technologies, instrument making, information technology, and a number of fundamental sciences, which leads to the need to develop competencies of higher, secondary, continuing, additional education, as well as the formation of a holistic growth system in chno the teaching staff. Filling the need for a new type of personnel to solve professional problems in the field of chemical and biological synthesis of pharmaceutical substances is a key task for the successful launch of modern pharmaceutical production, development and research of medicines.
“The cooperation of the centers and laboratories of the University together with the RIC AFS is the first step in creating innovative and scientific infrastructure. Interaction in this area allows us to solve the complex of problems of personnel policy in pharmaceuticals, including the development of fundamental and applied research in the field of drug development and technological processes, as well as the further implementation of development in production, ”commented Igor Narkevich , Rector of FSBEI HE SPFFU
The key to successful development of the pharmaceutical industry is not only the creation of modern pharmaceutical and medical industry enterprises, but also the technological re-equipment of production at existing sites. At the same time, the creation of small production sites equipped with modern equipment for the synthesis of APIs allows us to quickly expand the production line of large existing enterprises or to clarify the planned product portfolio for new companies.
Life Sciences Technology Park will be highly innovative. Thus, the share of innovative companies among planned residents will be more than 70%. The strengths of the Life Sciences technology park include an efficiently functioning organizational structure, which will combine Russian and foreign pharmaceutical companies of different sizes, including network partners. Such an organizational and economic model of interaction between the participants determines the significant competitiveness of both individual elements of the site and the technology park as a whole.
“The project presents the main technical and organizational solutions for the process of creating and organizing the work of the production zone, development requirements, necessary and detailed requirements for equipping (equipment) the site and the rationale for the choice of the proposed equipment or technological solution, estimated, estimated and other indicators that allow us to consider expediency and effectiveness of the project. The main areas of cooperation with the Finnish partner, Kotka, have been agreed. The integration of the project into the activities of the cluster participants is displayed, including the identification of potential key project participants among the cluster participants ”& nbsp; – said & nbsp; Valentina Chaplinskaya , expert, coordinator of large infrastructure projects at the PPP Russia-Southeast Finland.
In the course of work, the following tasks have already been solved:
- The idea of the project was worked out taking into account the participants and partners of the project;
- Identified strengths and weaknesses of the project;
- Assessed the effectiveness of the project;
- Conducted marketing research of the market, including St. Petersburg;
- Calculation of project income and expenses;
- A business model of the project was developed;
- A conclusion has been prepared on the effectiveness of investments at various levels of profitability.
The strengths of the project include thoughtful integration into the infrastructure of the Single Territory, which will offer competitive services to potential consumers, both among developing small businesses and large pharmaceutical manufacturing enterprises.
In general, the work of the Collective Stand of the first day, demonstrated the successes and most important achievements of the leading participants of the Cluster of Medical, Pharmaceutical Industry, Radiation Technologies, St. Petersburg, which can rightfully be proud of.
